Advanced search
Publication Cover
Expert Review of Hematology Volume 14, 2021 - Issue 4
Submit an article Journal homepage
1,648
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Paving the way to precision medicine in multiple myeloma

Shafqat Inama Clinical haematology, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Melbourne, AustraliaCorrespondence[email protected]
View further author information
,
Jeremy A. Rossb Precision Medicine, Oncology, AbbVie, North Chicago, IL, USAView further author information
,
Cyrille Touzeauc Service D’hématologie Clinique, Hotel Dieu, Nantes, France;d CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, FranceView further author information
,
Philippe Moreaue Department of Hematology, University Hospital, Nantes, FranceView further author information
,
Shaji K. Kumarf Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0001-5392-9284View further author information
ORCID Icon &
Simon J. Harrisong Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia;h Sir Peter MacCallum Department of Oncology, Melbourne University, Melbourne, AustraliaView further author information
Pages 323-327 | Received 23 Nov 2020, Accepted 16 Mar 2021, Published online: 12 Apr 2021

References

  • Kale J, Osterlund EJ, Andrews DWBCL-2. family proteins: changing partners in the dance towards death. Cell Death Differ. 2018 Jan;25(1):65–80.
  • Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202–208.
  • Touzeau C, Ryan J, Guerriero J, et al. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia. 2016 Mar;30(3):761–764.
  • Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014 Jan;28(1):210–212.
  • Jelinek T, Mihalyova J, Kascak M, et al. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol. 2019 Jan;94(1):E35–E37.
  • Bryce AH, Ketterling RP, Gertz MA, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009 Mar;94(3):380–386.
  • Warsame R, Kumar SK, Gertz MA, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015 May;1(5):e310.
  • Punnoose EA, Leverson JD, Peale F, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016 May;15(5):1132–1144.
  • Matulis SM, Gupta VA, Nooka AK, et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia. 2016 May;30(5):1086–1093.
  • Qin JZ, Ziffra J, Stennett L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005 Jul 15;65(14):6282–6293.
  • Kumar S, Kaufman JL, Gasparetto C, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017 Nov 30;130(22):2401–2409.
  • Moreau P, Chanan-Khan A, Roberts AW, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017 Nov 30;130(22):2392–2400.
  • Scheid C, Reece D, Beksac M, et al. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. 2015 Oct;95(4):316–324.
  • Kaufman JL, Gasparetto C, Schjesvold FH, et al. Phase I/II study evaluating the safety and efficacy of venetoclax in combination with dexamethasone as targeted therapy for patients with t(11;14) relapsed/refractory multiple myeloma. Blood. 2019;134(Supplement_1):926.
  • Mateos M-V, Moreau P, Dimopoulos MA, et al. A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. J clin oncol. 2020;38(15_suppl):TPS8554–TPS8554.
  • Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020 Dec;21; (12):1630-1642.
  • Jelinek T, Popkova T, Duras J, et al. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): a real-world cohort. Hematol Oncol. 2020 Aug;38(3):412–414.
  • Costa LC, Stadtmauer EA, Morgan G, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. EHA Lib. 2019 06 15;266992:PS1375.
  • Kaufman JL, Baz RC, Harrison SJ, et al. Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, ± bortezomib, in patients with relapsed/refractory multiple myeloma. J clin oncol. 2020;38(15_suppl):8511.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.